A clinical hold on an Antios Therapeutics drug has led to the end of a collaboration with Assembly Biosciences less than a year after their alliance began. The partners had hoped pairing their drugs with an approved Gilead Sciences antiviral would produce a combination hepatitis B treatment with the potential for a cure.
Four patients dosed with an experimental Assembly Biosciences hepatitis B treatment developed high levels of liver enzymes, a sign of drug-induced liver toxicity. The biotech has decided to stop further work on that drug and focus instead on developing its other clinical-stage hepatitis B drugs.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Chromis Therapeutics is developing small molecules that can reduce or eliminate the cccDNA from the nuclei of infected liver cells, and block reinfection mechanisms.
The list continued to grow of preventive services that people are entitled to receive without paying anything out of pocket. In 2014, the U.S. Preventive Services Task Force recommended two new services and tweaked a handful of others that had previously been recommended. Under the health law, preventive care that receives an “A” or “B” […]
There’s been a lot of hype around new Hep C drugs (cough, Gilead, cough), but less attention’s paid to Hepatitis B, a stunningly prevalent version of the virus that can lead to cirrhosis and liver cancer. Novira Therapeutics just raised $9 million in debt from 10 investors, according to a regulatory filing. The startup last year […]
An Indiana University spinout attracted investors from Johnson & Johnson Development Corp. and BioCrossroads with novel drugs to treat, and even potentially cure, patients with hepatitis B. Assembly Pharmaceuticals received an undisclosed amount for this seed round. This funding will finance the preclinical proof of concept and help the company establish its bio labs in San Francisco, […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.